 Patients who complete the Part 2 Week 28 visit in study KNS-760704-CL201 and patients with ALS who are actively receiving RTPB 6R-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydro-chloride monohydrate under Research IND 60,948 may be eligible to participate in this study. 